Longview Financial Advisors, Inc. Eli Lilly & CO Transaction History

Longview Financial Advisors, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$772.14 - $960.02 $30,885 - $38,400	-40 Reduced 2.44%	1,598 $1.42 Billion
Q1 2024 Aug 14, 2024	BUY	$592.2 - $792.28 $592 - $792	1 Added 0.06%	1,639 $1.27 Billion
Q4 2023 Oct 18, 2024	BUY	$525.19 - $619.13 $860,261 - $1.01 Million	1,638 New	1,638 $955 Million
Q4 2023 Aug 14, 2024	BUY	$525.19 - $619.13 $860,261 - $1.01 Million	1,638 New	1,638 $955 Million

4,007

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $717B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Longview Financial Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Longview Financial Advisors, Inc. with notifications on news.